By expert opinion, Circularity Healthcare is bringing about a radical change in noninvasive transdermal drug delivery, cardiovascular health, and neuroscience widely across the health care system.
We are proudly working with distinguished, world-class scientific and medical experts on cutting-edge research in multiple countries at the same time.
We have obtained pivotal and randomized, placebo-controlled, double-blind human clinical trial evidence and long-term positive user feedback with an exceptional safety and efficacy record.
We have launched operations in key countries in North America, Europe, and Asia and secured the support of leading institutions and local experts.
We have obtained certificate of registration to IS EN ISO13485:2012 (European Union) and ISO13485:2003 under CMDCAS (Canada) in 2015 supporting our entry into key countries.
For over eight years, we have received the highest five-star customer satisfaction ratings, with zero adverse side effect reports and some of the most promising benefits.
We cover neurology, oncology, endocrinology, cardiovascular, respiratory, dermatology, and other major fields.
We deploy a well-established platform business model validated by and marketed in conjunction with leading FDA-cleared diagnostics.
We offer affordable, promising upcoming treatments for the vast majority of the population with an exceptional safety and efficacy profile.
We have obtained a uniquely strong, sizeable patent portfolio in key countries coupled with several technological, legal, and regulatory safeguards.
We utilize world-class clinical research, product, technology, research and development resources, with years of advances in store.
Circularity Healthcare, LLC, is an emerging multinational leader in noninvasive transdermal and circulatory health technologies.
D’OXYVA® (deoxyhemoglobin vasodilator) is Circularity’s first clinically studied, trademarked, and patented transdermal delivery system, which is the latest breakthrough in the field of autonomic nervous system (ANS), cardiovascular, and microvascular applications. It is named after the two main mechanisms of action related to its solution: deoxyhemoglobin vasodilator.
Circularity’s mission is to change the standard of care, the dynamics of how health care is delivered at health care facilities and at home.
The benefits of Circularity Healthcare’s approach are numerous because microcirculation is regarded in the latest research from academia and the medical and complementary alternative health communities as the underlying cause of most chronic health complications. Noninvasive transdermal delivery has many advantages over oral, needle, and minimally invasive transdermal delivery methods.
D’OXYVA is advantageous for the patient, health care practitioner, and the entire health care system, providing substantial cost savings and improvement in quality of life. D’OXYVA is for a wide variety of health complications for people of all ages and backgrounds, both in combination with other therapies and as a stand-alone solution.
Circularity operates a state-of-the-art ISO 13485:2012 quality management system and supply chain and is seeking clearance for treating various widespread disease states via the U.S. FDA and in countries around the world for D’OXYVA.
Several major long-term trends are reshaping the health care industry worldwide, driving the demand for Circularity’s proprietary, patented technologies, such as the movement toward the outpatient setting; shrinking health care budgets; decreasing reimbursement for hospital stays, hospital outpatient centers, and treatments; increasing demand for post-hospitalization care; and the increasing role of telemedicine and telediagnostics tracking patient progress and satisfaction.
In addition, blockbuster pharmaceutical discoveries are costlier, and new medicine breakthroughs are more challenging to achieve than ever before. The market for health care technologies is driven by a high demand for minimally or noninvasive ultra-portable applications with low cost, low risk, low regulatory requirements, and short time to market that require little or no reimbursement.
Our people consider the following values essential to realizing our mission as an effective and efficient organization.
We at Circularity believe in a long-sought-after goal in health care: People should have access to one health application that solves most of their short- and long-term health issues without compromising other aspects of their health and can be used quickly, affordably, and without pain.
Therefore, our mission is to design, develop, manufacture, and market proprietary, advanced, and affordable technologies that significantly improve quality of life by improving some of the most essential physiological functions in the body.
The dearest objective of our people is to serve our stakeholders that make it possible for our company to deliver the best solutions to patients and consumers who benefit from our products, the doctors who recommend them, and the various channels that distribute them.
We do what we say and say what we do to excel and take responsibility in everything we offer.
Can you help us find new ways to help you? We always listen to people with a variety of backgrounds and constantly come up with valuable solutions to build value for all people engaged with our company.
We have been successfully building our company on the principle of an innovative lean and collaborative outsourced model with reliable partners. We provide affordable products with a wide variety of significant benefits to the great majority of people worldwide while being conscientious of the bottom line. This enables us to grow quickly and safely.
Our agility and precision are praised by our stakeholders as we tackle the unique challenges in a global business environment.
The benefits and potential risks of the products we offer and our company’s activities are shared openly and directly with all stakeholders.
We are building a world-class team that is dynamic and built on collaborative support trained by the best-in-practice tools.
Circularity Healthcare Announces Expansion with Global CRO of Series of Successful Pivotal Human Clinical Trials to Study Use of D’OXYVA® for Rapid, Economical and Noninvasive Home Treatment of Diabetic Foot Ulcers (DFU)
PASADENA, Calif., Feb. 1, 2021 5:31 AM PST (MORNINGSTAR) Addressing urgent and increased DFU problem related to pandemic lockdowns. Circularity Healthcare announced it had successfully executed a contract with the
LOS ANGELES (PRWEB) DECEMBER 11, 2019 Circularity is partnering with Telly Award-Winning “Behind the Scenes” to provide regular, ongoing, high-quality content from leading experts in a variety of fields with an
Switch To D'OXYVA®.
The only gentle, rapid, and painless transdermal solution without breaking the layers of the skin.
D’OXYVA® (deoxyhemoglobin vasodilator) biotechnology provides an inexpensive, simple and effective method of mild to severe chronic wound care. Its fully noninvasive transdermal approach delivers a host of benefits including but not limited to significant blood flow in the microcirculation (perfusion index), oxygen saturation (SpO2), nutrients, nerve stimulation (parasympathetic), which together are crucial for the complete and painless wound healing process.
Get in touch to avail D’OXYVA® for rapid chronic wound treatment.